Ladenburg Thalmann initiated coverage of CA Healthcare Acquisition with a rating of Buy
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/31/2021 | Buy | Ladenburg Thalmann | |
| 8/31/2021 | $14.75 | Buy | Ladenburg Thalmann |
Ladenburg Thalmann initiated coverage of CA Healthcare Acquisition with a rating of Buy
Ladenburg Thalmann initiated coverage of Compost America Holding with a rating of Buy and set a new price target of $14.75
15-12B - CA Healthcare Acquisition Corp. (0001832352) (Filer)
8-K - CA Healthcare Acquisition Corp. (0001832352) (Filer)
8-K - CA Healthcare Acquisition Corp. (0001832352) (Filer)
LumiraDx's common shares will commence trading on September 29, 2021 on Nasdaq under the ticker symbol "LMDX" The Merger values LumiraDx at $3.0 billion (excluding the amounts raised by CAHC in its initial public offering) LumiraDx Limited ("LumiraDx"), a next-generation point of care ("POC") diagnostic testing company and CA Healthcare Acquisition Corp. ("CAHC"), a special purpose acquisition company traded on Nasdaq, today announced the completion of the previously announced merger. CAHC stockholders approved the merger (the "Merger") during a special meeting held today and final voting results will be disclosed by CAHC on a Form 8-K to be filed with the Securities and Exchange Comm
CA Healthcare's Board Recommends Stockholders Vote "FOR" the Business Combination and "FOR" all of the related proposals All stockholders of CA Healthcare as of September 1st, 2021 are encouraged to vote their shares in advance of the Special Meeting Stockholders who need assistance voting their shares should contact CA Healthcare's proxy solicitor, Morrow Sodali, at 203-658-9400 or via email at [email protected] CA Healthcare Acquisition Corp. (NASDAQ:CAHC) ("CA Healthcare"), a publicly traded special purpose acquisition company, and LumiraDx Limited ("LumiraDx"), a next-generation point of care diagnostics testing company, announced that the U.S. Securities and Exchange Commis
Revised transaction terms adjust LumiraDx's pro forma valuation for the combined group from $5 billion to $3 billion (excluding $115 million raised by CA Healthcare Acquisition Corp ("CAHC") in its initial public offering). Terms establish a more attractive entry point for investors, and a highly compelling investment thesis on an absolute and relative basis Factors considered in revising the valuation include: the recent market environment for publicly traded diagnostic companies, general decline in COVID-19 testing market, and feedback from CAHC's advisors and shareholders LumiraDx has a roadmap of 10 new test approvals over the next 24 months on its platform, including Troponin,
SC 13G - CA Healthcare Acquisition Corp. (0001832352) (Subject)
SC 13G - CA Healthcare Acquisition Corp. (0001832352) (Subject)